Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Senaparib 10 mg and 20 mg in Healthy Chinese Subjects
NCT07019194Phase 1Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of senaparib in solid tumor (2 arms), sponsored by IMPACT Therapeutics. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 1 more. Started Jun 2024; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07019194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019194.